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Abstract
Objective: This study presents the results 
of two-period, two-treatment crossover 
investigations on 24 healthy Indian male 
subjects to assess the bioequivalence of 
two oral formulations containing 400 mg 
of dexibuprofen (CAS 51146-56-6). An at-
tempt was also made to study the phar-
macokinetics of dexibuprofen in the local 
population of Indian origin.
Method: Both of the formulations were 
administered orally as a single dose sepa-
rated by a one-week washout period. The 
concentration of dexibuprofen in plasma 
was determined by a validated HPLC 
method with UV detection using carbam-
azepine as internal standard. The formu-
lations were compared using the parame-
ters area under the plasma concentra-
tion-time curve (AUC0-t), area under the 
plasma concentration-time curve from 
zero to infinity (AUC0-∞), peak plasma 
concentration (Cmax), and time to reach 
peak plasma concentration (tmax).
Results: The results of this investiga-
tion indicated that there were no statisti-
cally significant differences between the 
logarithmically transformed AUC0-∞ and 
Cmax values of the two preparations. The 
90 % confidence interval for the ratio of 
the logarithmically transformed AUC0-t, 
AUC0-∞ and Cmax were within the 
bioequivalence limit of 0.8-1.25 and the 
relative bioavailability of the test formu-
lation was 99.04 % of that of reference 
formulationjok?.
Conclusion: Thus, these findings clear-
ly indicate that the two formulations are 
bioequivalent in terms of rate and extent 
of drug absorption. Both preparations 
were well tolerated with no adverse reac-
tions observed throughout the study.
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1. Introduction
Ibuprofen (CAS 15687-27-1) is one of the most frequent-
ly used, nonsteroidal anti-inflammatory drug (NSAID) 
that is effectively used for treating many different types 
of pain (osteoarthritis, rheumatoid arthritis and moder-
ate to severe post operative pain) [1, 2]. Dexibuprofen 
(CAS 51146-56-6) is the S-(+)-isomer of ibuprofen, a chi-
ral 2-arylpropionic acid derivative. In a recent collabora-
tive meta-analysis with individual NSAIDs proved that 
ibuprofen had the smallest risk of serious gastrointesti-
nal complications. However, several independent stud-
ies in which different in-vitro approaches were used to 
monitor the inhibition of the cyclooxygenases COX-1 
and COX-2 by ibuprofen jincomplete sentence! [3–7]. 
An interesting feature of ibuprofen, which is marketed in 
most countries as an equal mixture of R- and S-ibupro-
fen (racemate), is the unidirectional metabolic chiral in-
version of the in-vitro inactive (not prostaglandin syn-
thesis inhibiting) R-enantiomer to the prostaglandin 
synthesis inhibiting S-form [8–10]. This conversion of ra-
cemic ibuprofen to the active S-(+)-isomer may contrib-
ute to the variability in analgesia and may explain the 
poor relationship observed between plasma concentra-
tions of ibuprofen and the clinical response in acute pain 
and rheumatoid arthritis. (jPlease check the latter and 
the following sentencej) In [11–13] it has been reported 
that S-(+)-ibuprofen was more potent than the racemic 
formulation of ibuprofen with respect to its analgesic 
and anti-inflammatory properties, and it produced less 
acute gastric damage. Dionne and McCullagh [14] stud-
ied the analgesic effect of orally administered ibuprofen 
active S-(+)-isomer in the clinical oral surgery model of 
acute pain. The administration of 200 mg of S-(+)-ibu-
profen resulted in a greater analgesic effect than that of a 
racemic mixture containing approximately the same 
amount of active isomer. The analgesic onset was faster 
and the peak analgesia with only a small incidence of ad-
verse effects [14]jok?
Several high performance liquid chromatography 
(HPLC) methods have been published for the individual 
determination of ibuprofen. Mehvar et al. [15] described 
one liquid-chromatographic assay of ibuprofen enantiom-
ers in plasma with UV detection applying derivatization 
of ibuprofen with ethyl chloroformate and (S)-(–)-1(1-
napthyl)ethylamine. Vinci et al. [16] described one LC-
MS method for the determination of 14 NSAID includ-
ing ibuprofen in animal serum and plasma. An HPLC 
method for the estimation of ibuprofen in dog plasma 
was reported by Wang et al. [17]. In the present study, a 
simple HPLC method with UV detection has been de-
scribed using precipitation technology for the determi-
nation of dexibuprofen in human plasma.
Bioavailability and bioequivalence issues have been 
an increasing concern to drug regulatory authorities for 
the assessment of the safety and efficacy of drug prod-
ucts. As the number of synonym drug products increase, 
bioavailability issues become a major concern. Bio-
equivalence of two formulations of the same drug com-
prises equivalence with respect to the rate and extent of 
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absorption while the area under concentration time 
curve (AUC) generally serves as the characteristic of the 
extent of absorption [18, 19]. No individual parameter 
reliably measures the rate of absorption; for instance, 
the maximal drug concentration (Cmax) has been widely 
used, but it depends more on the fraction absorbed 
than the rate of absorbtion; the time required to reach 
the maximal concentration (tmax) depends on both ab-
sorption and elimination rates [20].
The main purpose of the present study was to evalu-
ate the relative bioavailability of 400 mg dexibuprofen 
tablet (test product) with that of the reference product, 
a tablet formulation also containing 400 mg dexibupro-
fen. In addition, an attempt was made to study the 
pharmacokinetics of dexibuprofen in the local popula-
tion of Indian origin.
2. Materials and methods
2.1 Materials and reagents
Acetonitrile and potassium dihydrogen phosphate were pur-
chased from Merck, Mumbai (India). All solvents used were of 
HPLC grade, whereas other chemicals and reagents were of 
analytical grade. Water was purified by a Milli-Q gradient sys-
tem of Millipore (Elix, Milli-Q A10 Academic) until a resistance 
of 18 MΩ was achieved. Blank human plasma with EDTA-K3 an-
ticoagulant was collected from the Clinical Pharmacological 
Unit (CPU) of the Bioequivalence Study Centre, Jadavpur Uni-
versity, Kolkata (India).
2.2 Products studied
Test product: Dexibuprofen 400 mg tablet (batch No. DI-0601, 
expiry date: October 2008). The test product was obtained from 
its manufacturer, Everest Formulations, Saproon, Solan (India).
Reference product: Dexibuprofen 400 mg tablet (batch No. 
10896039, expiry date: Jun, 2008. The reference product was 
purchased at a local pharmacy.
2.2 Study design
Twenty-four non-smoking, normal, healthy, Indian subjects 
took part in the study. They had not previously participated in 
another clinical trial nor donated blood during the preceding 
3–4 months, and had no history of alcohol or drug abuse. None 
had received prescription or over the counter drugs for at least 
4 weeks prior to the study day. They were aged between 18 and 
45 years (24.8 ± 3.78 years) with a body mass index between 18 
and 24 (22.11 ± 3.13). All of them underwent complete physical 
examination, vital signs (blood pressure and pulse) check-up, 
and electrocardiogram measurement with biochemical and he-
matological tests before enrolling for the study. None of them 
showed clinically significant abnormalities. The study was only 
initiated after the protocol and subject information forms had 
been approved by the Drugs Control General of India (DCGI), 
New Delhi and the Institutional Ethical Committee (IEC) of Ja-
davpur University, Kolkata (India). Informed consent was ob-
tained from all the subjects prior to the start of the study. The 
study was in compliance with Good Clinical Practice (GCP) and 
the revised Declaration of Helsinki. The study design was rand-
omized, single dose, fasting, two-period, two-sequence crosso-
ver with a one-week wash out period [21–24].
2.3 Drug administration and sample collection
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All the subjects assembled in the CPU ward at 6 a. m. on the 
study day of each session, after overnight fasting of 10 h. They 
did not consume any caffeinated or alcoholic beverages for at 
least 72 h prior to drug administration or during the study days. 
They received either of the study preparations and each served 
as their own control. According to the US Food and Drug Ad-
ministration (FDA) and European Agency for the Evaluation of 
Medicinal Products (EMEA) [25] regulations, the sampling 
schedule should be planned to provide a reliable estimate of 
the extent of absorption [26, 27]. This is generally achieved if 
AUC0-t is at least 80 % of AUC0-∞. Usually the sampling time 
should extend to at least three terminal elimination half-lives of 
the active ingredient. The time periods between the samplings 
should not exceed one terminal half-life [28]. A total of 12 blood 
samples were collected at 0 h (before drug administration) and 
at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 6.0, 8.0, 10.0, 12.0 and 24.0 h (after 
drug administration) in the test tubes with EDTA at each time 
point. Breakfast, lunch, and dinner were provided 3 h, 6 h, and 
13 h, respectively, after drug administration. Collected blood 
samples were centrifuged immediately; plasma was separated 
and stored frozen at  –20 °C with appropriate labeling of subject 
code number, study date, and collection time, till the date of 
analysis.
2.4 Sample preparation
To 1.0 ml of plasma in a 10 ml test tube, 100 µl of internal stan-
dard (IS, carbamazepine, CAS 298-46-4) at 1.0 µg/ml was added 
and then the tube was vortexed. For protein precipitation 1.0 ml 
acetonitrile was added, samples were vortexed, placed in the 
refrigerator for 15 min and centrifuged at 4000 rpm for 10 min. 
The supernatant layer was separated of which 20 µl was inject-
ed onto the HPLC column. Peak areas of dexibuprofen and IS 
were recorded.
2.5 Chromatographic conditions
Plasma samples were analyzed for dexibuprofen by HPLC with 
UV detection. The HPLC system (Knauer, Berlin, Germany) 
consisted of a solvent delivery pump (K 1001), a Rheodyne in-
jector and a variable UV-visible detector (K-2501) with Euro-
chrom 2000 software for integration. HPLC was carried out iso-
cratically at room temperature using an analytical column, 
Luna C18 (250 x 4.6, 5 µm particle size) from Phenomenex, 
USA. Elution was achieved with acetonitrile:10 mmol phos-
phate buffer (45:55, v/v) as the mobile phase. The sample was 
injected through the Rheodyne injector system fitted with 20 µl 
fixed loop. The effluent was monitored using UV detection at 
223 nm. The method was validated in compliance with stan-
dard guidelines [29].
2.6 Pharmacokinetic analysis
The following pharmacokinetic parameters were directly deter-
mined or calculated by a standard non-compartmental meth-
od. Both maximum plasma concentration (Cmax) and time to 
peak plasma concentration (tmax) were obtained directly from 
the analytical data. The elimination half-life (t1/2) was calculat-
ed as 0.693/Ke, where Ke is the apparent elimination rate con-
stant. Ke was, in turn, calculated as the slope of the linear re-
gression line of natural log-transformed plasma concentrations. 
The last seven quantifiable levels were used to determine Ke. 
The area under the plasma concentration-time curve (AUC0-t) 
was calculated from the measured levels, from time zero to the 
time of the last quantifiable level, by the linear trapezoidal rule. 
AUC0-∞ was calculated according to the following formula:
AUC0-∞ = AUC0-t + Clast / Ke
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where Clast is the last quantifiable plasma level. The tolerability 
of dexibuprofen was assessed by monitoring and subjects inter-
view regarding the potential presence of adverse events.
2.7 Statistical analysis
For each subject, descriptive statistics was used to evaluate-
jok? the estimated pharmacokinetic parameters. AUC0-t, 
AUC0-∞ and Cmax values were considered primary variables for 
bioequivalence analysis. Their log-transformed data were ana-
lyzed by an analysis of variance (ANOVA), including treatment, 
period and subject. The bioequivalence analysis was made ac-
cording to guidance of the Committee for Proprietary Medici-
nal Products (CPMP): the test product was considered bioequiv-
alent to the reference product if the 90 % confidence interval 
(CI) for the ratio between each parameter fell within the prede-
termined equivalence range of 80 – 125 % [25]. In addition, the 
nonparametric 90 % interval of the median differences of tmax 
was determined according to Hauschke et al. [18]. Tolerance 
data (vital sings, analytical results) were evaluated by Student’s 
t test of repeated measures. Statistical significance was consid-
ered at p≤0.05.
3. Results
During HPLC analysis, no interferences were observed 
in the chromatogram of the plasma sample (Fig. 1). The 
retention time for IS and dexibuprofen was 4.85 and 
14.21 min, respectively. The limit of quantification for 
dexibuprofen in plasma was 100 ng/ml with a coefficient 
of variation (CV) of 6.52 %. The relationship between 
concentration and peak area ratio (dexibuprofen:IS) was 
found to be linear within the range of 0.100 to 30 µg/ml. 
Quality control points at low, medium, and high levels 
(0.200, 12.0 and 24.0 µg/ml) were used to determine sta-
bility, absolute recovery and within-day and between-
day precision and accuracy. The within-day and be-
tween-day precision and accuracy data are summarized 
in Table 1.
Mean plasma concentration versus time curves after 
administration of reference and test products to healthy 
subjects are shown in Fig. 2. The original 24 subjects 
concluded the study. Table 2 summarizes the demo-
graphic and mean health parameters of all the partici-
pants. Mean values of pharmacokinetic parameters af-
ter administration of reference and test products to 
healthy subjects are summarized in Table 3. The limits 
of the 90 % CIs for the ratios of Cmax, AUC0-t, and AUC0-∞ 
for their log-transformed data fell within 0.80 to 1.25 
(Table 3). Nonparametric analysis according to the Wil-
coxon signed rank test did not show any statistically sig-
nificant differences between test and reference prod-
ucts (P < 0.05). The observed tmax values for the test 
product were within the acceptable limits (± 20 % of the 
mean values of the reference product).
j Fig. 1+2, Tab. 1–3 j
4. Discussion
The described analytical method used for the measure-
ment of dexibuprofen was shown to be accurate and 
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sensitive. The linearity achieved for this assay (0.100 to 
30 µg/ml) effectively covers the therapeutic range. The 
run time was 17.5 min (Fig. 1). The peak of dexibuprofen 
and IS were well resolved. Table 1 shows the data of be-
tween-day and within-day precision and accuracy. The 
mean (± SD) extraction recovery of dexibuprofen was 
89.36 ± 4.28 %, whereas that of carbamezepine (IS) was 
88.34 ± 3.87 %.
Throughout the stability tests, dexibuprofen proved 
stable in biological samples for at least three freeze and 
thaw cycles with a final mean recovery of 97.18 % and a 
coefficient of variation (CV) of 3.89 %. Dexibuprofen in 
plasma was stable at room temperature for at least 
24 h.
It can be observed from Table 2 that the subjects 
formed a homogeneous population in terms of age, 
weight, and body mass index. Dexibuprofen was well 
tolerated and there were no dropouts. Gastrointestinal 
disorders, the most common adverse effect associated 
with the use of NSAID, were not reported.
The elimination half-life (t1/2) of dexibuprofen was in 
the range 1.84 to 1.89 h. Thus, the one-week washout 
period was sufficient due to the fact that no sample pri-
or to administration in phase 2 showed any dexibupro-
fen levels. The time to reach maximum plasma concen-
tration (tmax) was 2.1 to 2.2 h after drug administration, 
and the last samples were sufficient for calculating at 
least 80 % of AUC0-∞. All calculated pharmacokinetic pa-
rameters summarized in Table 3 agree with the previ-
ously reported values [30]. Administration of the refer-
ence preparation produced a Cmax of 27.944 ± 1.002 µg/
ml at the time 2.208 ± 0.257 h (tmax), whereas the test 
product produced a Cmax of 26.972 ± 1.274 µg/ml at the 
time 2.125 ± 0.311 h (tmax). AUC0-t and AUC0-∞ of the test 
versus reference were 95.757 ± 2.928 µg ∙ h/ml versus 
96.687 ± 1.626 µg ∙ h/ml and 97.441 ± 2.706 µg ∙ h/ml l 
versus 98.406 ± 1.730 µg ∙ h/ml, respectively. Adminis-
tration of the reference product produced a Ke of 0.377 
± 0.014 h-1 with t1/2 of 1.840 ± 0.509 h, whereas the test 
product produced a Ke of 0.367 ± 0.021 h-1 with t1/2 of 
1.889 ± 0.413 h. On the basis of the comparison of the 
AUC0-t for dexibuprofen after single dose administra-
tion, the relative bioavailability of the test preparation 
was 99.04 % jofj(ok?) that of the reference prepara-
tion.
The aim of the bioequivalence trials is to assure in-
terchangeability between an innovator and a generic 
formula in terms of efficacy and safety. When a pharma-
cological effect is difficult to measure, the plasma levels 
of a drug may be used as an indicator of clinical activity. 
Therefore dexibuprofen plasma levels obtained in this 
study suggest an equal clinical efficacy of the two brands 
tested and provide pharmacokinetic data from the In-
dian population.
5. Conclusion
The 90 % CI of Cmax, AUC0-t and AUC0-∞ were in the ac-
ceptable range of 0.80–1.25. ANOVA (subject, period, 
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treatment) was applied to the Cmax, ln Cmax, AUC0-t and 
ln AUC0-t values. There was no statistically significant 
difference for the treatment values. Both formulations 
were equal in terms of rate and extent of absorption. On 
the basis of pharmacokinetic parameters studied, it can 
be concluded that the test product is bioequivalent with 
the reference product.
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Fig. 1: Chromatograms of (A) blank plasma, (B) blank plasma spiked with 10.0 µg/ml of dexibuprofen, (C) subject plasma con-
taining 4.9 µg/ml of dexibuprofen at 6.0bh after administration of 400 mg dexibuprofen tablet. Retention times of IS (carbam-
azepine) are 4.84 min (B) and 4.85 min (C); retention times of dexibuprofen are 14.35 min (B) and 14.21 min (C). No interfering 
peaks were observed at the retention times of IS and dexibuprofen in the chromatogram of blank plasma.
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Fig. 2: Mean (± SD, n=24) plasma concentration-time profiles 
after administration of test and reference formulations in 
healthy Indian subjects. The curves were obtained by plotting 
time (h) on the x-axis and plasma concentration (µg/ml) on 
the y-axis.
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Table 2: Demographic and health parameters of healthy sub-
jects considered in the bioequivalence study.
Age
(yr)
Weight
(kg)
Height
(cm)
BMI
(kg/m2)
Mean 24.8 60.2 165 22.11
SD   3.78   4.31 0.06  3.13
SD = standard deviation; BMI = body mass index.
Table 3: Mean (± SD, n = 24) pharmacokinetic parameters of 400 mg dexibuprofen tablets of the test and reference formulation.
Parameter Test Reference 90 % CI(log-transformed data)
AUC0-t (µg ∙ h /ml) 95.757 ± 2.928 96.687 ± 1.626 0.988919 – 1.008748
AUC0-∞ (µg ∙ h /ml) 97.441 ± 2.706 98.046 ± 1.730 0.994422 – 1.011938
Cmax (µg/ml) 26.972 ± 1.274 27.944 ± 1.002 0.977821 – 1.032926
tmax (h) 2.125 ± 0.311 2.208 ± 0.257
Ke (h-1) 0.367 ± 0.021 0.377 ± 0.014
t1/2 (h) 1.889 ± 0.413 1.840 ± 0.509
AUC0-t = area under the plasma concentration-time curve from 0 to t h; AUC0-∞ = area under the plasma concentration-time curve from 0 to 
infinity; Cmax = maximum plasma concentration; tmax = time to reach maximum plasma concentration; Ke = elimination rate constant; t1/2 = 
elimination half-life; CI = confidence interval. Data are presented as mean values ± SD.
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Table 1: Within-day and between-day precision and accuracy 
of the HPLC method.
Concentration
(µg/ml)
Within day (n = 6) Between day (n = 18)
Accuracy 
(%)
Precision 
(CV %)
Accuracy 
(%)
Precision 
(CV %)
0.200 95.82 6.45 93.61 8.67
6.00 98.82 4.16 97.05 6.48
12.00 99.57 3.31 102.11 4.55
n = 6/18: mean value obtained after 6/18 determinations; CV = co-
efficient of variation expressed as %.
